drugset / Trial / NCT00832494

Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer

NCT00832494

Phase 1/2 Completed 105 enrolled Antisoma Research
RandomizedParallel-groupOpen-labelTreatment

Summary

This study was designed to test the addition of DMXAA (now known as ASA404) to carboplatin and paclitaxel in patients with NSCLC.

Timeline

Start
2004-09
Primary completion
2007-08
Completion
2007-08

Drugs

EvaluationDrugModalityDoseRoute
Subject ASA404 Unknown 600 mg/m2
Subject ASA404 Unknown 1200 mg/m2
Subject ASA404 Unknown 1800 mg/m2
Background Carboplatin Small molecule 6 unknown
Background Paclitaxel Small molecule 175 mg/m2